Irreversible sensorineural hearing loss due to Imatinib

Attili, Venkata Satya Suresh; Bapsy, P P; Anupama, G.; Dasappa, Lokanatha

doi:10.1016/j.leukres.2007.11.039

Cited by 27 publications

(22 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Very recently, sporadic cases of ototoxicity due to different molecular targeted agents such as imatinib or bortezomib have been reported [9,10]. Our case highlights the importance of drug-induced ototoxicity and its impact on quality of life.…”

Section: To the Editormentioning

confidence: 62%

Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer

et al. 2008

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 62%

Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer

et al. 2008

View full text Add to dashboard Cite

“…Ototoxicity is a side effect that can develop due to the use of chemotherapy drugs [5,6] . Cisplatin is one of the drugs which is best known to have this side effect [7,8] .…”

Section: Discussionmentioning

confidence: 99%

“…Because these two chemotherapy drugs are used sequentially or combined with other chemotherapy drugs, clinical studies have not been planned. In the literature, erlotinib and imatinib dependent ototoxicity have been reported, as they are tyrosine kinase inhibitors that effect ototoxicity along a different pathway [1,6,9] . When we examine the studies relating tyrosine kinase inhibitors to hearing loss, many of them displayed mechanisms related to EGFR and HER [10,11] .…”

Section: Discussionmentioning

confidence: 99%

“…Examination revealed no additional pathology of the ear. Yet another case of sensorineural hearing loss due to the usage of imatinib was chronic myelogenous leukemia [6] . After a 400 mg/day dose of imatinib was administered for five days, bilateral hearing loss developed [6] .…”

Section: Discussionmentioning

confidence: 99%

“…Yet another case of sensorineural hearing loss due to the usage of imatinib was chronic myelogenous leukemia [6] . After a 400 mg/day dose of imatinib was administered for five days, bilateral hearing loss developed [6] . In addition to this, sensorineural hearing loss due to erlotinib was reported in a patient [12] .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of Lapatinib and Trastuzumab for Ototoxic Effects

Eryılmaz

Demirci²,

Günel³

et al. 2016

Int Adv Otol

View full text Add to dashboard Cite

Original Article INTRODUCTIONTrastuzumab (Herceptin®; Genentech, California, San Francisco, USA) is used for treating human epidermal growth factor receptor 2 (HER2)-positive breast cancers. Trastuzumab is a humanized recombinant monoclonal antibody that acts on the extracellular portion of the HER2 protein [1] . Lapatinib (Tykerb®; Glaxo-Smith Kline) is a tyrosine kinase inhibitor that suppresses epidermal growth factor 1 (EGF-1) and intracellular phosphorylation of the HER-2/neu receptor. In studies with trastuzumab, cardiotoxicity is stated as the most common side effect [2] . The known side effects of lapatinib are the reduction of the left ventricular ejection fraction, interstitial lung disease/pneumonitis, dizziness, fatigue, severe diarrhea, dry cough, white sores in the mouth or lips, nosebleeds, nausea, stomach pain, jaundice, loss of appetite, aspartate aminotransferase (AST) changes, alanine aminotransferase (ALT) changes, and hematological changes [3,4] . To our knowledge, the ototoxicity of these chemotherapeutic agents has not yet been studied. The aim of this study is to identify whether these agents are ototoxic in rats and to determine the dose dependency of the ototoxicity. MATERIALS and METHODSThe study was approved by the Animal Experiments Ethical Committee of Adnan Menderes University (64583101/2013/038). A total of 48 male rats aged 4-8 months were randomly divided into six groups. All rats were subjected to distortion product otoacoustic emissions (DPOAE) on the first day after being anesthetized with ketamine/xylazine. Group 1 (control group) received Evaluation of Lapatinib and Trastuzumab for Ototoxic EffectsOBJECTIVE: Trastuzumab and lapatinib are widely used chemotherapeutic agents. Our aim in this study was to assess the possible ototoxicity of these chemotherapeutic agents. MATERIALS and METHODS:Forty-eight rats were divided into six groups: Group 1 (control, n=8) received intraperitoneal saline for 7 days. Group 2 (n=8) and Group 3 (n=8) received 10 mg/kg and 30 mg/kg single doses of intraperitoneal trastuzumab, respectively. Lapatinib was administered by oral gavage to Group 4 (n=8) at 100 mg/kg/day and to group 5 (n=8) at 300 mg/kg/day for 7 days. Group 6 (n=8) received only one dose of 10 mg/kg intraperitoneal trastuzumab; subsequently, Group 6 received one dose of lapatinib at 100 mg/kg/day by oral gavage for 7 days. Before any medication was administered, distortion product emissions (DPOAE) were obtained. DPOAE tests were performed again on the rats on day 7, after which the mastoid bullas were harvested. The apoptosis degree was evaluated by the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) procedure. RESULTS:The lapatinib 300 and lapatinib+trastuzumab groups (p=0.008 and p=0.001, respectively) were significantly different from the control group according to the spiral ganglion TUNEL. Apoptosis in the organ of corti was statistically different compared with the control group in the lapatinib 100, lapatinib 300, and lapatinib+trastuzu...

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2008

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Irreversible sensorineural hearing loss due to Imatinib

Cited by 27 publications

References 4 publications

Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer

Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer

Evaluation of Lapatinib and Trastuzumab for Ototoxic Effects

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About